mindray

ChemBook

t , 2 , C , , , 2



A A1 LDL . L ( ) CKD. [1,4]



Hypertriglyceridemia in CKD results from the delayed catabolism of triglyceride-rich lipoproteins. Apo A1 synthesis is reduced in patients with CKD, and the activation of LCAT by Apo A1 is also decreased. The maturation of HDL precursors is consequently affected. Increased Lp(a) is caused by post-translation modification of lipoproteins related to CKD.

F 3. D [4]

C CKD

K D : I G (KDIG) 2013. A CKD ( ) (G, C, LDL-C, HDL-C). F A CKD 50, / . [5]

F A D : .I A D, . I

A D . [6,7]

C LDL-C KDIG (2013) CKD GF, . A GF, A D, . [5]

H LDL-C CKD ( ), . [4] CKD : 10- <50 . [5]

A D CKD, . A CKD

1. François Mach, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020(1)41, 111–188, https://doi.org/10.1093/eurheartj/ehz455

2. Lv JC, Zhang LX. Prevalence and Disease Burden of Chronic Kidney Disease. Adv Exp Med Biol. 2019; 1165:3-15. doi: 10.1007/978-981-13-8871-2_1

3. Webster, A., Nagler, E., Morton, R. et al. Chronic kidney disease.The Lancet. 2017; 389: 1238-1252. https://-doi.org/10.1016/S0140-6736(16)32064-5

4. Ferro, C.J., Mark, P.B., Kanbay, M. et al. Lipid management in patients with chronic kidney disease.Nat Rev Nephrol. 14, 727–749 (2018). https://doi.org/10.1038/s41581-018-0072-9

5. Wanner C, Tonelli M, et al. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014 Jun;85(6):1303-9. doi: 10.1038/ki.2014.31

6. JJennifer L Larsen, et al. Lipid Status After Pancreas-Kidney Transplantation. Diabetes Care Jan. 1992, 15 (1) 35-42; DOI: 10.2337/diacare.15.1.35

7. Claudio Ponticelli, et al. Treatment of dyslipidemia in kidney transplantation. Expert Opinion on Drug Safety. (2020) 19 :3, 257-267, DOI: 10.1080/14740338.2020.1732921

Wech

www.mindray.com

/ : E G-C L A CKD -210285 4 -20210430

mindray
healthcare within reach